Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02934139 · ClinicalTrials.gov registry record · Phase 1

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)

A Phase 1 study of Cystic Fibrosis, sponsored by Nivalis Therapeutics.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT02934139 is a Phase 1 study of Cystic Fibrosis that has completed, run by Nivalis Therapeutics. The registered enrollment target is 32 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02934139, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by Nivalis Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The present study is designed to assess the safety and tolerability of escalating, multiple ascending doses of Cavosonstat (N91115) in healthy subjects.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Cavosonstat

Study Locations (1)

Colorado

  • DaVita Clinical Research - Lakewood

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2016-10
Est. Completion 2017-01
Phase Phase 1

Sponsor

Nivalis Therapeutics

10 total trials

What the Registry Record Tells You About NCT02934139

The ClinicalTrials.gov registry entry for NCT02934139 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (82% lower). The listed sponsor is Nivalis Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02934139 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT02934139 about?

NCT02934139 is a clinical study titled "MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)". The present study is designed to assess the safety and tolerability of escalating, multiple ascending doses of Cavosonstat (N91115) in healthy subjects.

What is the current status of trial NCT02934139?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-10. Estimated completion is 2017-01.

What conditions does trial NCT02934139 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT02934139?

The interventions under investigation include: Placebo (OTHER), Cavosonstat (DRUG).

Who is sponsoring clinical trial NCT02934139?

This trial is sponsored by Nivalis Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02934139 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.